Patents by Inventor David Dolphin

David Dolphin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5648485
    Abstract: A .beta.,.beta.'-dihydroxy meso-substituted chlorin, bacteriochlorin or isobacteriochlorin compound having the formula (I) or (II): ##STR1## wherein M is a metal. A novel method for synthesizing the compound of formula (I) or (II) comprises the steps of:a. osmylating a .beta...beta.'-unsubstituted, meso-substituted porphyrin to form an osmate ester at the .beta.,.beta.'-position, andb. reducing the osmate ester to form the corresponding .beta.,.beta.'-dihydroxy meso-substituted chlorin, bacteriochlorin or isobacteriochlorin of formula (I) or (II).
    Type: Grant
    Filed: October 26, 1994
    Date of Patent: July 15, 1997
    Assignee: University of British Columbia
    Inventors: David Dolphin, Christian Bruckner
  • Patent number: 5512675
    Abstract: A method for synthesizing a porphocyanine having the formula: ##STR1## where each R is ethyl, comprises either: (1) treating 3,3'-4,4'-tetraethyl-5,5'-bisaminomethyl-2,2'-dipyrromethane with a 10-fold excess of DDQ or(2) treating 3,3'-4,4'-tetraethyl-5,5'-diformyl 2,2'-dipyrromethane with ammonia, followed by column chromatography purification and evaporating to dryness the eluant containing the purified product.
    Type: Grant
    Filed: June 15, 1993
    Date of Patent: April 30, 1996
    Assignee: The University of British Columbia
    Inventors: Hang Tang, Lily Xie, Tilak Wijesekera, David Dolphin
  • Patent number: 5405957
    Abstract: A group of novel expanded porphyrin-like compounds, porphacyanine (Pc) and porphacyanine-like compounds, having absorption maxima in the range of 400-850 nanometers is useful in detecting and treating targeted tissues, cells and viruses. The use of the Pc of the invention permits the irradiation to comprise wavelengths other than those absorbed by blood. The Pc of the invention may also be conjugated to target-specific moieties such as immunoglobulins or fragments thereof to target specific tissues or cells for the radiation treatment. Use of these materials permits greater depth of treatment penetration and greater specificity in targeting tissues or cells. Coupled with an appropriate paramagnetic ion or radioisotope, the Pc of the invention is suitable for use in nuclear magnetic resonance imaging and radioimaging.
    Type: Grant
    Filed: October 30, 1992
    Date of Patent: April 11, 1995
    Assignee: The University of British Columbia
    Inventors: Hang Tang, Lily Xie, Tilak Wijesekera, David Dolphin
  • Patent number: 5399583
    Abstract: A group of hydro-monobenzoporphyrins "green porphyrins" (Gp) having absorption maxima in the range of 670-780 nanometers is useful in treating disorders or conditions which are subject to hematoporphyrin derivative (HPD) treatment in the presence of light, or in treating virus, cells and tissues generally to destroy unwanted targets. The use of the Gp of the invention permits the irradiation for therapy to use wavelengths other than those absorbed by blood. The Gp of the invention may also be conjugated to ligands specific for receptor or to specific immunoglobulins or fragments thereof to target specific tissues or cells for the radiation treatment. Use of these materials permits lower levels of drug to be used, thus preventing side reactions which might destroy normal tissues.
    Type: Grant
    Filed: January 25, 1994
    Date of Patent: March 21, 1995
    Assignee: The University of British Columbia
    Inventors: Julia G. Levy, David Dolphin, Jack J. Chow, Ethan Sternberg
  • Patent number: 5308608
    Abstract: A group of hydro-dibenzoporphyrins prepared by di-Diels-Alder additions at the A and C rings of the appropriate divinyl porphyrins have absorption maxima in the range of 700-820 nanometers and are photosensitizing agents. These compounds are useful in treating disorders or conditions which are subject to hematoporphyrin derivative (HPD) treatment in the presence of light, or in treating biological materials generally to destroy unwanted targets such as viruses, cells and tissues. The use of the compounds of the invention permits irradiation with wavelengths other than those absorbed by blood. The compounds of the invention may also be conjugated to ligands specific for receptors or to specific immunoglobulins or fragments thereof to home to target tissues or cells for the radiation treatment. Use of these materials permits lower levels of photosensitizer to be used, thus preventing side reactions which might destroy normal tissues.
    Type: Grant
    Filed: September 4, 1992
    Date of Patent: May 3, 1994
    Assignee: University of British Columbia
    Inventors: David Dolphin, Paul Y. Hin, Tilak Wijesekera
  • Patent number: 5283255
    Abstract: A group of hydro-monobenzoporphyrins "green porphyrins" (Gp) having absorption maxima in the range of 670-780 nanometers is useful in treating disorders or conditions which are subject to hematoporphyrin derivative (HPD) treatment in the presence of light, or in treating virus, cells and tissues generally to destroy unwanted targets. The use of the Gp of the invention permits the irradiation for therapy to use wavelengths other than those absorbed by blood. The Gp of the invention may also be conjugated to ligands specific for receptor or to specific immunoglobulins or fragments thereof to target specific tissues or cells for the radiation treatment. Use of these materials permits lower levels of drug to be used, thus preventing side reactions which might destroy normal tissues.
    Type: Grant
    Filed: September 11, 1992
    Date of Patent: February 1, 1994
    Assignee: The University of British Columbia
    Inventors: Julia G. Levy, David Dolphin, Jack J. Chow, Ethan Sternberg
  • Patent number: 5171749
    Abstract: A group of hydro-monobenzoporphyrins "green porphyrins" (Gp) having absorption maxima in the range of 670-780 nanometers is useful in treating disorders or conditions which are subject to hematoporphyrin derivative (HPD) treatment in the presence of light, or in treating virus, cells and tissues generally to destroy unwanted targets. The use of the Gp of the invention permits the irradiation for therapy to use wavelengths other than those absorbed by blood. The Gp of the invention may also be conjugated to ligands specific for receptor or to specific immunoglobulins or fragments thereof to target specific tissues or cells for the radiation treatment. Use of these materials permits lower levels of drug to be used, thus preventing side reactions which might destroy normal tissues.
    Type: Grant
    Filed: June 20, 1991
    Date of Patent: December 15, 1992
    Assignee: University of British Columbia
    Inventors: Julia G. Levy, David Dolphin, Jack J. Chow, Ethan Sternberg
  • Patent number: 5149708
    Abstract: A group of hydro-dibenzoporphyrins prepared by di-Diels-Alder additions at the A and C rings of the appropriate divinyl porphyrins have absorption maxima in the range of 700-820 nanometers and are photosensitizing agents. These compounds are useful in treating disorders or conditions which are subject to hematoporphyrin derivative (HPD) treatment in the presence of light, or in treating biological materials generally to destroy unwanted targets such as viruses, cells and tissues. The use of the compounds of the invention permits irradiation with wavelengths other than those absorbed by blood. The compounds of the invention may also be conjugated to ligands specific for receptors or to specific immunoglobulins or fragments thereof to home to target tissues or cells for the radiation treatment. Use of these materials permits lower levels of photosensitizer to be used, thus preventing side reactions which might destroy normal tissues.
    Type: Grant
    Filed: February 28, 1991
    Date of Patent: September 22, 1992
    Assignee: University of British Columbia
    Inventors: David Dolphin, Paul Y. Hin, Tilak Wijesekera
  • Patent number: 5095030
    Abstract: A group of hydro-monobenzoporphyrins "green porphyrins" (Gp) having absorption maxima in the range of 670-780 nanometers is useful in treating disorders or conditions which are subject to hematoporphyrin derivative (HPD) treatment in the presence of light, or in treating virus, cells and tissues generally to destroy unwanted targets. The use of the Gp of the invention permits the irradiation to use wavelengths other than those absorbed by blood. The Gp of the invention may also be conjugated to ligands specific for receptor or to specific immunoglobulins or fragments thereof to target specific tissues or cells for the radiation treatment. Use of these materials permits lower levels of drug to be used, thus preventing side reactions which might destroy normal tissues.
    Type: Grant
    Filed: September 28, 1989
    Date of Patent: March 10, 1992
    Assignee: University of British Columbia
    Inventors: Julia G. Levy, David Dolphin, Jack K. Chow, Ethan Sternberg
  • Patent number: 4920143
    Abstract: A group of hydro-monobenzoporphyrins "green porphyrins" (Gp) having absorption maxima in the range of 670-780 nanometers is useful in treating disorders or conditions which are subject to hematoporphyrin derivative (HPD) treatment in the presence of light, or in treating virus, cells and tissues generally to destroy unwanted targets. The use of the Gp of the invention permits the irradiation to use wavelengths other than those absorbed by blood. The Gp of the invention may also be conjugated to ligands specific for receptor or to specific immunoglobulins or fragments thereof to target specific tissues or cells for the radiation treatment. Use of these materials permits lower levels of drug to be used, thus preventing side reactions which might destroy normal tissues.
    Type: Grant
    Filed: July 19, 1988
    Date of Patent: April 24, 1990
    Assignee: University of British Columbia
    Inventors: Julia G. Levy, David Dolphin, Jack K. Chow, Ethan Sternberg
  • Patent number: 4883790
    Abstract: A group of hydro-monobenzoporphyrins "green porphyrins" (Gp) having absorption maxima in the range of 670-720 nanometers is useful in treating disorders which are subject to hematoporphyrin derivative (HPD) treatment in the presence of light. The use of the Gp of the invention permits the irradiation to comprise wavelengths other than those absorbed by blood. The Gp of the invention may also be conjugated to receptor ligands or to specific immunoglobulins or fragments thereof to target specific tissues or cells for the radiation treatment. Use of these materials permits lower levels of drug to be used, thus preventing side reactions which might destroy normal tissues.
    Type: Grant
    Filed: April 23, 1987
    Date of Patent: November 28, 1989
    Assignee: University of British Columbia
    Inventors: Julia G. Levy, David Dolphin, Jack K. Chow